OMER Omeros Corporation

24.79
-0.92  -4%
Previous Close 25.71
Open 25.63
Price To book 0.00
Market Cap 1.09B
Shares 43,939,000
Volume 927,441
Short Ratio 16.43
Av. Daily Volume 851,164

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated "as soon as possible" - company noted May 17, 2017.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 2 initiated Feb 2014. Trial was placed on hold due to preclinical concerns. To resume with with dosing limitations
OMER824
Huntington disease
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)